Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
| العنوان: | Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience |
|---|---|
| المؤلفون: | Pei-Ying Wu, Ya-Min Cheng, Meng-Ru Shen, Yi-Chun Chen, Yu-Fang Huang, Cheng-Yang Chou |
| المصدر: | Frontiers in Oncology Frontiers in Oncology, Vol 10 (2020) |
| بيانات النشر: | Frontiers Media S.A., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, peritoneal cancer, Bevacizumab, medicine.medical_treatment, bevacizumab, lcsh:RC254-282, survival, 03 medical and health sciences, platinum sensitivity, 0302 clinical medicine, Internal medicine, Carcinoma, Medicine, Adverse effect, drug-related side effects, Original Research, Chemotherapy, business.industry, Hazard ratio, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Serous fluid, 030104 developmental biology, ovarian cancer, 030220 oncology & carcinogenesis, Cohort, progression, fallopian cancer, business, Ovarian cancer, medicine.drug |
| الوصف: | This study aimed to determine the real-world, long-term prognostic impacts, and adverse effects (AEs) of bevacizumab (BEV) in Asian patients with ovarian/tubal/peritoneal cancers. We retrospectively reviewed the medical records of consecutive patients with ovarian/tubal/peritoneal cancer on front-line chemotherapy with or without BEV (Cohort 1) and those who relapsed following chemotherapy and/or BEV (Cohort 2) between 2011 and 2018 in a tertiary medical centre. Patient characteristics, BEV dosages, clinical outcomes, and AEs were analyzed. Hazard ratios for disease progression and death were analyzed using a cox proportional regression model. Benefits of BEV used throughout triweekly, in terms of improved progression-free survival (PFS) and overall survival (OS), were observed at a dosage of 7.5–15 mg/kg among advanced-stage Cohort 1 patients. A progression-free interval of |
| اللغة: | English |
| تدمد: | 2234-943X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509dca15069f549673303693278d1457Test http://europepmc.org/articles/PMC7372289Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....509dca15069f549673303693278d1457 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2234943X |
|---|